About this trial
This is a prospective, multicenter, open-label study designed to evaluate the safety and tolerability of propranolol hydrochloride in combination with toripalimab and platinum-based chemotherapy as perioperative treatment in patients with resectable non-small cell lung cancer (NSCLC). Propranolol hydrochloride is a beta- adrenergic blocking agent which is associated with augment of immune cell responses. Propranolol hydrochloride may improve the responses of immune checkpoint inhibitors in treating patients with resectable NSCLC.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Sign a written informed consent form before any research-related procedures;
Age ≥ 18 years and ≤ 75 years;
ECOG PS score 0-1;
Have self-awareness, be willing and have the ability to complete the questionnaire (stress score for all patients);
Disqualifiers
Concurrent participation in another interventional clinical study or receiving other investigational drugs, unless participating in an observational clinical study.
Prior exposure to any anti-PD-1 or anti-PD-L1, PD-L2, CD137, CTLA-4 antibody therapy, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
Systemic treatment with Chinese patent medicines with anti-tumor indications or immunomodulatory drugs (including thymosin, interferon, and interleukins; except for local administration to control pleural effusion or ascites) within 2 weeks prior to first dose.
Current use of oral or intravenous beta-blockers (e.g., atenolol, bisoprolol, carvedilol, labetalol, metoprolol, nadolol, sotalol, etc.) that cannot be safely switched to non-beta-blocker alternatives. Current subjects should have a washout period of at least 14 days with adequate transition period.
Trial design
Single group
Treatments tested in this trial
Propranolol Hydrochloride
DrugOral propranolol hydrochloride will be administered at escalating dose levels using a conventional 3+3 dose-escalation design. Three planned dose levels are 10 mg BID, 10 mg TID and 20 mg BID. Propranolol will be administered in combination with neoadjuvant toripalimab and platinum-based chemotherapy, followed by postoperative maintenance treatment with propranolol and toripalimab.
Toripalimab
DrugToripalimab will be administered intravenously at a dose of 240 mg on Day 1 of each 21-day cycle, in combination with propranolol hydrochloride and platinum-based chemotherapy for 3-4 neoadjuvant cycles. Following surgical resection, toripalimab will be continued as postoperative maintenance therapy according to the study protocol.
Chemotherapy
DrugParticipants will receive platinum-based doublet chemotherapy selected according to tumor histology. For nonsquamous NSCLC, chemotherapy will consist of pemetrexed in combination with cisplatin or carboplatin. For squamous NSCLC, chemotherapy will consist of a taxane (paclitaxel, nab-paclitaxel, liposomal paclitaxel, paclitaxel polymeric micelles, or docetaxel) in combination with cisplatin or carboplatin. Chemotherapy will be administered intravenously every 3 weeks for 3-4 neoadjuvant cycles, in combination with propranolol hydrochloride and toripalimab, followed by multidisciplinary evaluation for surgical resection.
Treatment groups
Trial outcomes
Primary outcomes
Incidence of Dose-Limiting Toxicities (DLTs)
The number and percentage of participants experiencing dose-limiting toxicities at each propranolol dose level during the protocol-defined DLT assessment period. DLTs will be used to guide dose escalation in the conventional 3+3 design.
Incidence and Severity of Adverse Events (AEs)
The number and percentage of participants experiencing adverse events (AEs), treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and immune-related adverse events (irAEs). Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.
Secondary outcomes
Recommended Phase II Dose (RP2D) of Propranolol
The recommended Phase II dose of propranolol hydrochloride in combination with toripalimab and platinum-based doublet chemotherapy, determined based on the safety, tolerability, and DLT findings during Phase Ib dose escalation.
Pathological Complete Response (pCR) Rate
The percentage of participants achieving pathological complete response, defined as the absence of residual viable tumor cells in both the primary tumor bed and sampled regional lymph nodes following neoadjuvant treatment, as determined by pathological examination of surgical specimens.
Major Pathological Response (MPR) Rate
The percentage of participants achieving major pathological response, defined as 10% or less residual viable tumor cells in the primary tumor bed following neoadjuvant treatment, regardless of residual viable tumor cells in regional lymph nodes.
Objective Response Rate (ORR)
The percentage of participants achieving a complete response (CR) or partial response (PR), as assessed by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Second Xiangya Hospital of Central South University
Lead sponsor
Shanghai Junshi Bioscience Co., Ltd.
Collaborator